Even with the COVID-19 emergency measures, payers still had an eye on the potential flood of gene therapies for rare diseases brewing in the pipeline, and were pondering new ways to pay for them.
Achieving genuine human connection is a crucial part of survival. We all want to feel seen and heard, whether it’s on a casual level during a conversation about work, or on a humorous level exchanging the adventures of parenting, or at the very deep level of discussing and sharing mental health challenges. When it comes down to it, we want to be understood and supported, not necessarily by everyone we know but by the people who matter to us most. We want – we need – empathy. And when it comes to health, and managing the healthcare journey, this concept is no different.
The values of leading pharmaceutical brands have skyrocketed during the COVID-19 pandemic; Johnson & Johnson retains the top position.
The long-awaited digital transformation of life sciences has arrived. It went from a promise to a need.
Med Ad News sits down with Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories. He has more than 20 years of experience in the pharmaceutical industry with extensive knowledge and understanding of generics.
It is vital that, from the beginning of a medicine’s development, a regulatory strategy is built into all activities so companies may optimize value, control costs and reduce risks – all while ensuring proper compliance. If any step is missed along the way, lifescience companies will encounter roadblocks in the form of delays on approval cycles and lack of proper data control, which can impact the long-term revenue for the medicine.
In December 2021, the FDA issued draft guidance to lifescience researchers on evaluating EHR and claims data in studies to support regulatory decisions. This new draft guidance covers using real-world data from these sources to support regulatory decisions on both safety and effectiveness.
Patient support for these populations can greatly impact their overall well-being and willingness to adhere to prescribed therapies, but is also critical to alleviating the inherent anxiety accompanying the diagnosis and treatment journey in rare disease. To help ensure an optimum experience, the best patient support programs will address these concerns by blending the empathy of human connection with the scale of technology.
Few industries affect consumers on a more personal level than the healthcare industry. Pharma companies, in particular, have a unique challenge in making more meaningful customer connections.
Thanks to the meteoric rise of digital health, the role of data and analytics has also become central across the drug development life cycle, impacting every touch point from pipeline research and development to clinical trial design and implementation. A critical area that has fallen short, however, is applying a commensurate level of enthusiasm and expense for market research in the early phase as that afforded to downstream commercialization efforts. Compounding this challenge is the continued marginalization of disenfranchised communities.
